190 related articles for article (PubMed ID: 28957961)
1. Antineutrophil cytoplasmic antibody-associated vasculitis and malignancy.
Wester Trejo MAC; Bajema IM; van Daalen EE
Curr Opin Rheumatol; 2018 Jan; 30(1):44-49. PubMed ID: 28957961
[TBL] [Abstract][Full Text] [Related]
2. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.
van Daalen EE; Rizzo R; Kronbichler A; Wolterbeek R; Bruijn JA; Jayne DR; Bajema IM; Rahmattulla C
Ann Rheum Dis; 2017 Jun; 76(6):1064-1069. PubMed ID: 27899372
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013.
Rahmattulla C; Berden AE; Wakker SC; Reinders ME; Hagen EC; Wolterbeek R; Bruijn JA; Bajema IM
Arthritis Rheumatol; 2015 Dec; 67(12):3270-8. PubMed ID: 26246307
[TBL] [Abstract][Full Text] [Related]
4. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
5. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
Heijl C; Harper L; Flossmann O; Stücker I; Scott DG; Watts RA; Höglund P; Westman K; Mahr A;
Ann Rheum Dis; 2011 Aug; 70(8):1415-21. PubMed ID: 21616914
[TBL] [Abstract][Full Text] [Related]
6. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Malignancy Prior to Antineutrophil Cytoplasmic Antibody-associated Vasculitis Compared to the General Population.
van Daalen EE; Rahmattulla C; Wolterbeek R; Bruijn JA; Bajema IM
J Rheumatol; 2017 Mar; 44(3):314-318. PubMed ID: 28089971
[TBL] [Abstract][Full Text] [Related]
8. Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China.
Han XY; Li ZY; Zhao MH; Little MA; Chen M
Arthritis Res Ther; 2024 May; 26(1):113. PubMed ID: 38822382
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Menopause and Primary Ovarian Insufficiency in Women Treated for Antineutrophil Cytoplasmic Antibody-Associated Vasculitides.
Tuin J; Sanders JS; van Beek AP; Hoek A; Stegeman CA
Arthritis Rheumatol; 2016 Apr; 68(4):986-92. PubMed ID: 27023359
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
11. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
Tesar V; Hruskova Z
Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
[TBL] [Abstract][Full Text] [Related]
12. Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.
Shi L
Rheumatol Int; 2017 Nov; 37(11):1779-1788. PubMed ID: 28956128
[TBL] [Abstract][Full Text] [Related]
13. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
Rutgers A; Kallenberg CG
Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
[TBL] [Abstract][Full Text] [Related]
14. Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US.
James KE; Xiao R; Merkel PA; Weiss PF
Arthritis Care Res (Hoboken); 2017 Sep; 69(9):1377-1383. PubMed ID: 27813340
[TBL] [Abstract][Full Text] [Related]
15. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
16. The complications of vasculitis and its treatment.
King C; Harper L; Little M
Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):125-136. PubMed ID: 30526892
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide?
Sattui SE; Spiera RF
Rheum Dis Clin North Am; 2019 Aug; 45(3):379-398. PubMed ID: 31277751
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
20. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
